Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• The study focuses on drug exposure and follow-up duration for zilovertamab vedotin.
• Participants included individuals diagnosed with metastatic solid tumors.
• The follow-up duration was essential to assess the ongoing effects of the treatment.
• Understanding this data may guide future treatment protocols for metastatic tumors.